HALOZYME THERAPEUTICS, INC. · Exercise / conversion · Common Stock

What does this filing report?

An SEC Form 4 filing for HALOZYME THERAPEUTICS, INC. records an exercise / conversion involving Common Stock on October 8, 2026. The reported quantity was 20,000. The filing date is October 8, 2026. This is one transaction record; amounts are not allocated among any joint reporting owners.

The acquisition category describes how securities were received. It does not by itself establish a cash purchase of common stock. Read the transaction code definitionsand the original filing before interpreting the amounts.

Filing footnotes & remarks

F1

The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on December 3, 2025 in accordance with Rule 10b5-1. The sales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2028.

F2

Represents a weighted average sales price per share. The shares were sold at prices ranging from $107.480 to $108.290. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

F3

Represents a weighted average sales price per share. The shares were sold at prices ranging from $108.530 to $109.520. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

F4

Represents a weighted average sales price per share. The shares were sold at prices ranging from $109.530 to $110.510. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

F5

Represents a weighted average sales price per share. The shares were sold at prices ranging from $110.530 to $111.210. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

F6

Represents a weighted average sales price per share. The shares were sold at prices ranging from $110.360 to $111.350. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

F7

Represents a weighted average sales price per share. The shares were sold at prices ranging from $111.380 to $112.360. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

F8

Represents a weighted average sales price per share. The shares were sold at prices ranging from $112.400 to $113.190. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

F9

Represents a weighted average sales price per share. The shares were sold at prices ranging from $113.590 to $113.860. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

F10

Represents a weighted average sales price per share. The shares were sold at prices ranging from $107.480 to $108.475. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

F11

Represents a weighted average sales price per share. The shares were sold at prices ranging from $108.480 to $109.470. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

F12

Represents a weighted average sales price per share. The shares were sold at prices ranging from $109.510 to $110.500. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

F13

Grant to Reporting Person of options, exercisable over a 4-year period measured from the date of grant, 25% after 12 months, then 1/48th of the Option Shares per month thereafter. The date of grant was February 14, 2018.

Footnotes are reproduced as plain text from the current source filing. For the full context, read the original SEC filing.